Fda grants highest level of approval to the next generation of impella rp to treat right heart failure

Danvers, mass.--(business wire)--abiomed's (nasdaq: abmd) newest right heart pump, the impella rp with smartassist, has received u.s. food and drug administration (fda) pre-market approval (pma) as safe and effective to treat acute right heart failure for up to 14 days. impella rp with smartassist is the first single-access temporary percutaneous ventricular support device with dual-sensor technology. impella rp with smartassist is an innovative advancement of impella rp, which was granted a pm
ABMD Ratings Summary
ABMD Quant Ranking